Treatment with the experimental oral therapy ATH-1105 significantly reduced nerve damage, improved motor function, and prolonged survival in preclinical models of amyotrophic lateral sclerosis (ALS), a study reports. The work was funded by ATH-1105’s developer Athira Pharma, which plans to move the…
FundaMental Pharma’s investigational molecule FP802 reduced neurological disability, protected nerve cells, and prolonged survival in a mouse model of amyotrophic lateral sclerosis (ALS), according to recent research. The molecule also protected tissue from glutamate toxicity, a type of cellular toxicity that’s implicated…
Mutations in the C9ORF72 gene may lead to amyotrophic lateral sclerosis (ALS) and the related disorder frontotemporal dementia (FTD) in part by boosting the production of a powerful inflammatory protein called interleukin 17A (IL-17A), recent preclinical research suggests. Inhibiting IL-17A via genetic manipulations or…
Myrobalan Therapeutics will use a $400,000 grant from the ALS Association — along with $24 million in new financing — to help advance the development of its oral CSF1 receptor (CSF-1R) inhibitor program, intended to reduce neuroinflammation and promote nerve repair in people with amyotrophic lateral sclerosis…
A new compound that significantly extended survival in a mouse model of amyotrophic lateral sclerosis (ALS) by blocking the activity of a group of proteins called MAP4Ks has been identified by researchers. The molecule was associated with modest benefits, but researchers believe it can…
A research team at Ball State University has received a $20,000 donation from the Todd Siebert Memorial Foundation supporting work into better understanding and treating amyotrophic lateral sclerosis (ALS) caused by C9orf72 mutations. Awarded to Philip Smaldino, PhD, a cell biology professor at the Indiana school, and…
Enrollment is complete in a Phase 2 trial testing InFlectis BioScience’s oral candidate IFB-088 (icerguastat) in people with amyotrophic lateral sclerosis (ALS), the company has announced. The trial (NCT05508074) enrolled a total of 50 adults with bulbar-onset ALS, a form of the disease that first affects the…
More than a third of people diagnosed with amyotrophic lateral sclerosis (ALS) also showed signs of frontotemporal dementia (FTD), according to a new study of brain tissue. In more than 90% of tissues examined, patients had clumps of the TDP-43 protein, a hallmark of…
The ALS Association awarded $400,000 to University of Missouri-Columbia School of Medicine and its NextGen Precision Health Initiative as part of its program to encourage more amyotrophic lateral sclerosis (ALS) patients living in rural areas to take part in clinical trials. The university’s 2023 Trial Capacity Award…
AcuraStem has secured nearly $7 million in grant funding from the National Institutes of Health (NIH) and the Department of Defense (DOD) to accelerate the development of therapies for amyotrophic lateral sclerosis (ALS) and related diseases. Coming on the heels of a…
Get regular updates to your inbox.